Pancreatic Cancer Research

ResearcherMasaryk UniversityActive in the last 2 years

Jan Hlavsa

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5086200746. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 3 papers

Papers 16

  1. Ex-Vivo 3D Cellular Models of Pancreatic Ductal Adenocarcinoma: From Embryonic Development to Precision Oncology. Co-author DOI 10.1097/mpa.0000000000002393↗
  2. Artificial intelligence in pancreatic cancer histopathology and diagnostics - implications for clinical decisions and biomarker discovery? Co-author DOI 10.1186/s13008-025-00158-w↗
  3. Integrated clinical-bio logical infrastructure for precision oncology in pancreatic adenocarcinoma - experience with REDCap implementation in an academic setti… Co-author DOI 10.48095/ccko2025464↗
  4. Minimal invasive surgery of pancreatic cancer at the Department of Surgery of Masaryk university hospital Brno, Czech Republic. Co-author DOI 10.33699/pis.2024.103.4.122-131↗
  5. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. Co-author DOI 10.4149/neo_2020_200408n372↗
  6. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. Co-author DOI 10.3390/jcm9082440↗
  7. Radiofrequency ablation in pancreatic cancer. Co-author DOI 10.33699/pis.2019.98.11.441-449↗
  8. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection Co-author PMID 31064193↗
  9. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical… Co-author DOI 10.21873/cgp.20090↗
  10. Tumor grade as significant prognostic factor in pancreatic cancer: validation of a novel TNMG staging system. Co-author DOI 10.4149/neo_2018_171012n650↗
  11. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Co-author DOI 10.1038/tpj.2016.55↗
  12. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗
  13. [Current status regarding surgical treatment of pancreatic cancer in the Czech Republic]. Co-author PMID 27226268↗
  14. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13000-015-0272-6↗
  15. [Standardization of pancreatic cancer specimen pathological examination]. Co-author PMID 24720716↗
  16. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Co-author DOI 10.1007/s00280-013-2246-2↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zdeněk Kala · 13 shared papers, 2013–2025 · strength 1.28
  2. Vladimír Procházka · 7 shared papers, 2015–2025 · strength 1.12
  3. Michal Eid · 5 shared papers, 2021–2025 · strength 1.02
  4. Petr Moravčík · 4 shared papers, 2024–2025 · strength 0.90
  5. Petr Vaňhara · 3 shared papers, 2025 · strength 0.72
  6. Petra Weselá · 2 shared papers, 2025 · strength 0.51
  7. Ivana Aćimović · 2 shared papers, 2025 · strength 0.45
  8. Ondřej Slabý · 5 shared papers, 2015–2021 · strength 0.45
  9. Igor Kišš · 4 shared papers, 2015–2020 · strength 0.33
  10. Natalia Gabło · 3 shared papers, 2018–2020 · strength 0.29
  11. Martin Loveček · 4 shared papers, 2016–2020 · strength 0.28
  12. Ján Trnka · 1 shared paper, 2025 · strength 0.22
  13. Stanislava Martínková · 1 shared paper, 2025 · strength 0.22
  14. Martin Oliverius · 3 shared papers, 2013–2017 · strength 0.14
  15. Pavel Souček · 3 shared papers, 2013–2017 · strength 0.14
  16. Beatrice Mohelníková-Duchoňová · 3 shared papers, 2013–2017 · strength 0.14
  17. R Gürlich · 2 shared papers, 2016–2018 · strength 0.13
  18. Markéta Hermanová · 2 shared papers, 2015–2018 · strength 0.12
  19. Petra Vychytilova‐Faltejskova · 2 shared papers, 2015–2018 · strength 0.12
  20. Petr Karásek · 2 shared papers, 2015–2018 · strength 0.12
  21. Jiřı́ Mayer · 1 shared paper, 2021 · strength 0.12
  22. Lumír Kunovský · 1 shared paper, 2021 · strength 0.12
  23. Radmila Lemstrová · 2 shared papers, 2017 · strength 0.11
  24. David J. Hughes · 2 shared papers, 2017 · strength 0.11
  25. Ioana Berindan‐Neagoe · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.